Early Targeted Combination Treatment With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs and Long‐Term Outcomes in Rheumatoid Arthritis: Ten‐Year Follow‐Up Results of a Randomized Clinical Trial

The short‐term outcomes of remission‐targeted treatments of rheumatoid arthritis (RA) are well‐established, but the long‐term success of such strategies is speculative, as is the role of early add‐on biologics. We assessed the 10‐year outcomes of patients with early RA treated with initial remission‐targeted triple combination of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), 7.5‐mg prednisolone, and additional infliximab (IFX) or placebo infusions.

[1]  J. Askling,et al.  Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden , 2017, JAMA internal medicine.

[2]  C. Strehl,et al.  Will we ever have better glucocorticoids? , 2017, Clinical immunology.

[3]  T. Möttönen,et al.  Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. , 2016, Clinical and experimental rheumatology.

[4]  S. Ajeganova,et al.  Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study , 2016, Scandinavian journal of rheumatology.

[5]  P. Hannonen,et al.  Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis , 2016, The Journal of Rheumatology.

[6]  T. Stijnen,et al.  Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment , 2016, Annals of Internal Medicine.

[7]  D. Furst,et al.  Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. , 2015, Rheumatology.

[8]  G. Haugeberg,et al.  Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway , 2015, Arthritis Research & Therapy.

[9]  M. Hochberg,et al.  Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis , 2015, Arthritis Research & Therapy.

[10]  J. Katz,et al.  Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Study , 2014, Arthritis care & research.

[11]  C. Lanzani,et al.  AB0176 Association between Polymorphisms in Beta-Adducin and Sodium/Calcium Exchanger 1 and SLE with and without Nephritis , 2014 .

[12]  F. Breedveld,et al.  Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension , 2014, The Journal of Rheumatology.

[13]  D. Solomon,et al.  Patterns of Disease‐Modifying Antirheumatic Drug Use in Rheumatoid Arthritis Patients After 2002: A Systematic Review , 2013, Arthritis care & research.

[14]  P. Hannonen,et al.  Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial , 2013, Annals of the rheumatic diseases.

[15]  J. Schoones,et al.  What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review , 2013, Annals of the rheumatic diseases.

[16]  P. Hannonen,et al.  Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. , 2013, Clinical and experimental rheumatology.

[17]  M. Suarez‐Almazor,et al.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.

[18]  P. Hannonen,et al.  Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study) , 2012, Annals of the rheumatic diseases.

[19]  P. Hannonen,et al.  Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial , 2010, Arthritis research & therapy.

[20]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[21]  P. Hannonen,et al.  The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. , 2009, Arthritis and rheumatism.

[22]  Olivier Meyer,et al.  Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study , 2008, Arthritis research & therapy.

[23]  H. Mäkinen,et al.  Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. , 2006, Clinical and experimental rheumatology.

[24]  T. Saxne,et al.  Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[25]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .

[26]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[27]  M. A. van 't Hof,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.